Epidemiology of multiple sclerosis, Rev Neurol (Paris), vol.172, issue.1, pp.3-13, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01255824
Épidémiologie de la sclérose en plaques : la particularité française, Rev Neurol (Paris), vol.165, issue.8, pp.671-676, 2009. ,
, Définition et chiffres -Fondation Sclérose en plaques
La sclérose en plaques -Historique, épidémi, p.10 ,
Multiple sclerosis, Lancet Lond Engl. avr, vol.359, issue.9313, pp.1221-1252, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-00996686
Genetics of multiple sclerosis: an overview and new directions, Cold Spring Harb Perspect Med, vol.8, issue.7, 2018. ,
Multiple sclerosis genetics, Lancet Neurol ,
Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity, Hum Mol Genet, vol.7, issue.8, pp.1229-1263, 1998. ,
B-lymphocyte alloantigens associated with multiple sclerosis, Lancet Lond Engl, vol.2, issue.7998, pp.1261-1266, 1976. ,
Genetic basis for clinical expression in multiple sclerosis, Brain, vol.125, issue.1, pp.150-158, 2002. ,
HLA-DR15 haplotype and multiple sclerosis: a huge review, Am J Epidemiol, vol.165, issue.10, pp.1097-109, 2007. ,
Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease, 13. International Multiple Sclerosis Genetics Consortium, vol.55, pp.851-62, 2000. ,
The multiple sclerosis genomic map: role of peripheral immune cells and resident microglia in susceptibility, Consorti -International Multiple Sclerosis Genetics, p.143933, 2017. ,
Modelling genetic susceptibility to multiple sclerosis with family data, Neuroepidemiology, vol.40, issue.1, pp.1-12, 2013. ,
Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability, Mult Scler Relat Disord, vol.29, pp.130-136, 2019. ,
Migrant studies in multiple sclerosis, Prog Neurobiol, vol.47, issue.4-5, pp.425-473, 1995. ,
Role of return migration in the emergence of multiple sclerosis in the French West Indies, Brain, vol.128, issue.12, pp.2899-910, 2005. ,
Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration, J Neurol, vol.258, issue.6, pp.1140-1149, 2011. ,
Environmental factors in the development of multiple sclerosis, Rev Neurol (Paris), vol.174, issue.6, pp.372-379, 2018. ,
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosurg Psychiatry, vol.82, issue.10, pp.1132-1173, 2011. ,
Therapeutic potential of vitamin D for multiple sclerosis, Curr Med Chem, vol.15, issue.5, pp.499-505, 2008. ,
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution, Genome Res, vol.20, issue.10, pp.1352-60, 2010. ,
Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?, Brain, vol.133, issue.7, pp.1869-88, 2010. ,
Clinical implications of a possible role of vitamin D in multiple sclerosis, J Neurol, vol.256, issue.9, pp.1468-79, 2009. ,
Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle, 27. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25, vol.254, pp.471-478, 2007. ,
, Hydroxyvitamin D levels in serum at the onset of multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.11, issue.3, pp.266-71, 2005.
A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.79, issue.2, pp.152-159, 2008. ,
Immunomodulatory effects of vitamin D in multiple sclerosis, Brain, vol.132, issue.5, pp.1146-60, 2009. ,
Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.14, issue.9, pp.1220-1224, 2008. ,
Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis, Ann Neurol, vol.68, issue.2, pp.193-203, 2010. ,
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis, Ann Neurol, vol.72, issue.2, pp.234-274, 2012. ,
Smoking is a risk factor for multiple sclerosis, Neurology, vol.61, issue.8, p.1122, 2003. ,
,
, Neurol Barc Spain, vol.24, issue.3, pp.177-80, 2009.
Potential risk factors for multiple sclerosis in Rio de Janeiro: a case-control study, Arq Neuropsiquiatr, vol.67, issue.2A, pp.229-263, 2009. ,
Cigarette smoking and incidence of multiple sclerosis, Am J Epidemiol, vol.154, issue.1, pp.69-74, 2001. ,
Parental smoking at home and the risk of childhood-onset multiple sclerosis in children, Brain, vol.130, issue.10, pp.2589-95, 2007. ,
Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.7, pp.788-93, 2011. ,
Smoking worsens multiple sclerosis prognosis: two different pathways are involved, J Neuroimmunol, vol.281, pp.23-34, 2015. ,
Effect of Smoking Cessation on Multiple Sclerosis Prognosis, JAMA Neurol, vol.72, issue.10, pp.1117-1140, 2015. ,
Infectious mononucleosis, Clin Transl Immunol, vol.4, issue.2, p.33, 2015. ,
Epstein-Barr Virus Infection and antibody synthesis in patients with multiple sclerosis, Arch Neurol, vol.40, issue.7, pp.406-414, 1983. ,
Epstein-Barr Virus antibodies in multiple sclerosis, Arch Neurol, vol.37, issue.2, pp.94-100, 1980. ,
An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis, PLOS ONE. 1 sept, vol.5, issue.9, p.12496, 2010. ,
Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production, Eur J Clin Microbiol Infect Dis, vol.29, issue.7, pp.857-66, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00589489
Epstein-Barr virus in pediatric multiple sclerosis, JAMA, vol.291, issue.15, pp.1875-1884, 2004. ,
primary infection with the Epstein-Barr virus and risk of multiple sclerosis, Ann Neurol, vol.67, issue.6, pp.824-854, 2010. ,
Environmental changes and epidemiology of multiple sclerosis in the French West Indies, J Neurol Sci, vol.286, issue.1, pp.58-61, 2009. ,
Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway, J Immunol, vol.191, issue.7, pp.3827-3864, 2013. ,
rhumatismes inflammatoires et auto-immunité, Rev Rhum, vol.85, issue.1, pp.19-24, 2018. ,
Nutrition et sclérose en plaques : le point de la littérature, Nutr Clin Métabolisme, vol.32, issue.1, pp.67-80, 2018. ,
, Qu'est-ce que la sclérose en plaques ?, Sclérose en plaques (SEP) [Internet]. Inserm
,
Chapter 1 -Clinical nanifestations of multiple sclerosis: an overview, Minagar A, éditeur. Multiple Sclerosis ,
,
Aspects cliniques, physiopathologiques, et thérapeutiques de la sclérose en plaques, EMC -Neurol, vol.1, issue.4, pp.415-57, 2004. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology, vol.46, issue.4, pp.907-918, 1996. ,
La sclérose en plaques -PDF, 2019. ,
Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014. ,
MS: an inflammatory or a degenerative disease?, Neurologie.com ,
Pathology of multiple sclerosis: where so we stand?, Contin Lifelong Learn Neurol, vol.19, issue.4, pp.901-922, 2013. ,
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy, Trends Mol Med, vol.7, issue.3, pp.115-136, 2001. ,
Modulation de la réponse immunitaire dans le cerveau par la barrière hémato-encéphalique : implication en sclérose en plaques, 2012. ,
,
Animal models of Multiple Sclerosis, Eur J Pharmacol, vol.759, pp.182-91, 2015. ,
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool, Nat Neurosci, vol.14, issue.9, pp.1142-1151, 2011. ,
The autoimmune concept of multiple sclerosis, Presse Médicale, vol.44, issue.4, pp.103-115, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02147770
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis, Proc Natl Acad Sci, vol.103, issue.15, pp.5941-5947, 2006. ,
Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs, J Immunol, vol.191, issue.9, pp.4531-4540, 2013. ,
Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases, J Immunol, vol.193, issue.5, pp.2438-54, 2014. ,
Mast cell transcripts are increased within and outside multiple sclerosis lesions, J Neuroimmunol, vol.195, issue.1, pp.176-85, 2008. ,
Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients, Ann Neurol, vol.37, issue.1, pp.63-69, 1995. ,
Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Médecine Interne, vol.34, issue.8, pp.479-86, 2013. ,
The pathogenesis and basis for treatment in multiple sclerosis, Clin Neurol Neurosurg, vol.106, issue.3, pp.246-254, 2004. ,
Autoimmune T cell responses in the central nervous system, Nat Rev Immunol, vol.9, issue.6, pp.393-407, 2009. ,
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Clin Exp Immunol, vol.162, issue.1, pp.1-11, 2010. ,
Cytokines and effector T cell subsets causing autoimmune CNS disease, FEBS Lett, vol.585, issue.23, pp.3747-57, 2011. ,
Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?, Biochim Biophys Acta BBA -Mol Basis Dis, vol.1812, issue.2, pp.246-51, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00652650
Th17 cell, the new player of neuroinflammatory process in multiple sclerosis, Scand J Immunol, vol.74, issue.1, pp.1-13, 2011. ,
La sclérose en plaques, vol.300, 2017. ,
Migration et pathogénicité des lymphocytes T CD8 dans les maladies du système nerveux central. médecine/sciences, vol.31, pp.748-55, 2015. ,
Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF, J Neuroimmunol, vol.196, issue.1-2, pp.159-65, 2008. ,
Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions, Brain Pathol Zurich Switz, vol.14, issue.1, pp.1174-83, 2000. ,
Effector and regulatory B cells in multiple sclerosis, Clin Immunol, vol.1, pp.11-25, 2017. ,
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS, Neurology, vol.66, issue.4, pp.576-584, 2006. ,
The morbidity of multiple sclerosis, Q J Med, vol.83, issue.300, pp.325-362, 1992. ,
McAlpine's multiple sclerosis ,
Urinary, faecal and sexual dysfunction in patients with multiple sclerosis, J Neurol, vol.246, issue.11, pp.1027-1059, 1999. ,
Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis, J Urol, vol.154, issue.1, pp.169-73, 1995. ,
Fatigue et sclérose en plaques, Ann Réadapt Médecine Phys, vol.49, issue.6, pp.265-71, 2006. ,
Fatigue et sclérose en plaques, Prat Neurol -FMC, vol.5, issue.1, pp.49-56, 2014. ,
The impact of fatigue on patients with multiple sclerosis, Can J Neurol Sci J Can Sci Neurol, vol.21, issue.1, pp.9-14, 1994. ,
,
, Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis, Pain, vol.154, issue.5, pp.632-674, 2013.
,
The prevalence of cognitive impairment in a community survey of multiple sclerosis, Br J Clin Psychol, vol.30, issue.4, pp.333-381, 1991. ,
Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study, Psychol Med, vol.21, issue.1, pp.59-68, 1991. ,
Chapitre 1 -Signes et symptômes de la sclérose en plaques ,
, , pp.3-78, 2017.
,
, Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.76, issue.4, pp.519-545, 2005.
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS, Neurology, vol.63, issue.2, pp.335-344, 2004. ,
Major depression in multiple sclerosis: a population-based perspective, Neurology, vol.61, issue.11, pp.1524-1531, 2003. ,
Dépression et sclérose en plaques, Rev Neurol (Paris), vol.165, pp.156-62, 2009. ,
Anxiety disorders and their clinical correlates in multiple sclerosis patients, Mult Scler Houndmills Basingstoke Engl, vol.13, issue.1, pp.67-72, 2007. ,
Anxiété et dépression dans la sclérose en plaques : à propos de 100 patients tunisiens, Inf Psychiatr, vol.90, issue.5, pp.381-387, 2014. ,
Modifications de l'expérience émotionnelle dans la sclérose en plaques : une étude en neuropsychologie et en IRMf, Rev Neurol (Paris), vol.174, pp.154-159, 2018. ,
, Troubles psychiques et neuropsychologiques dans la sclérose en plaques
, Académie nationale de médecine | Une institution dans son temps, 2003.
,
, Sclérose en plaques
, Syndrome cliniquement isolé -la prise en charge thérapeutique
,
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-73, 2018. ,
McDonald diagnostic criteria for multiple sclerosis: 2017 (current) | Radiology Reference Article | Radiopaedia.org ,
, , 2018.
,
Imagerie du système nerveux central dans la sclérose en plaques, Presse Médicale, vol.39, issue.3, pp.349-58, 2010. ,
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, issue.1, pp.121-128, 2001. ,
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain, vol.120, issue.11, pp.2059-69, 1997. ,
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes, J Neurol Neurosurg Psychiatry, vol.77, issue.7, pp.830-833, 2006. ,
Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, J Neuroimmunol, vol.180, issue.1-2, pp.17-28, 2006. ,
Intrathecal oligoclonal IgG synthesis in multiple sclerosis, J Neuroimmunol, vol.262, issue.1-2, pp.1-10, 2013. ,
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis ?, Neurology, vol.70, issue.13, pp.1079-83, 2008. ,
Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual, Mult Scler Houndmills Basingstoke Engl, vol.18, issue.5, pp.587-91, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00826736
,
, Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis, Ann Neurol, vol.53, issue.2, pp.222-228, 2003.
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome, J Neuroimmunol, vol.257, issue.1-2, pp.76-81, 2013. ,
The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature, J Neurol, vol.264, issue.3, pp.453-66, 2017. ,
Prognostic value of free light chains lambda and kappa in early multiple sclerosis, Mult Scler J, vol.23, issue.11, pp.1496-505, 2017. ,
Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.21, issue.10, pp.1251-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01842463
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, p.1352458518765666, 2018. ,
Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course, Mult Scler Houndmills Basingstoke Engl, vol.17, pp.335-378, 2010. ,
Soluble CD27 levels in cerebrospinal fluid as a prognostic biomarker in clinically isolated syndrome, JAMA Neurol, vol.01, issue.3, pp.286-92, 2017. ,
Neuromyelitis optica and anti-aquaporin 4 antibody-distinct from multiple sclerosis, Rinsho Byori, vol.57, issue.3, pp.262-70, 2009. ,
Defining distinct features of anti-MOG antibody associated central nervous system demyelination, Ther Adv Neurol Disord, vol.29, 2018. ,
, Sclérose en plaques | SEP -Procédure de diagnostic
,
Les potentiels évoques visuels gardent-ils encore un intérêt diagnostique dans la sclérose en plaques ?, Rev Neurol, vol.172, p.87, 2016. ,
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome, Neurology, vol.72, issue.9, pp.800-805, 2009. ,
Les syndromes radiologiquement isolés, Prat Neurol -FMC, vol.1, issue.1, pp.25-33, 2010. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983. ,
, VIDAL -Sclérose en plaques -Prise en charge
,
11 -Sclérose en plaques ,
, , pp.268-86, 2012.
La prise en charge des poussées de sclérose en plaques en 2016, Prat Neurol -FMC, vol.7, issue.2, pp.166-73, 2016. ,
,
,
, Evidencebased guideline update : Plasmapheresis in neurologic disorders : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, vol.76, pp.294-300, 2011.
Traitements immunomodulateurs et immunosuppresseurs dans les maladies inflammatoires et auto-immunes ,
,
,
,
Clinical and demographic predictors of long-term disability in patients with relapsingremitting multiple sclerosis: a systematic review, Arch Neurol, vol.63, issue.12, pp.1686-91, 2006. ,
Actualités thérapeutiques de la sclérose en plaques, Rev Médecine Interne. 1 août, vol.31, issue.8, pp.575-80, 2010. ,
, Fiche info -AVONEX 30 microgrammes/0,5 ml, solution injectable -Base de données publique des médicaments
,
, Fiche info -BETAFERON 250 microgrammes/ml, poudre et solvant pour solution injectable -Base de données publique des médicaments
,
, Fiche info -EXTAVIA 250 microgrammes/ml, poudre et solvant pour solution injectable -Base de données publique des médicaments
,
, Fiche info -REBIF 22 microgrammes, solution injectable en stylo prérempli -Base de données publique des médicaments
,
, Fiche info -REBIF 44 microgrammes, solution injectable en seringue préremplie -Base de données publique des médicaments
,
, Fiche info -PLEGRIDY 125 microgrammes, solution injectable en stylo prérempli -Base de données publique des médicaments
,
, Quels sont les principaux effets indésirables des traitements par interféron bêta ?
, , 2016.
Interférons bêta dans le traitement de la sclérose en plaques: risque de microangiopathie thrombotique et de syndrome néphrotique -Lettre aux professionnels de santé -ANSM : Agence nationale de sécurité du médicament et des produits de santé ,
,
, TECFIDERA gélule gastrorésistante (diméthyle fumarate) : désormais disponible en ville
,
,
, Fiche info -TECFIDERA 240 mg, gélule gastro-résistante -Base de données publique des médicaments
357 -Immunomodulateurs, Méga Guide STAGES IFSI, 2015. ,
Azathioprine for multiple sclerosis, J Neurol Neurosurg Psychiatry. févr, vol.80, issue.2, pp.131-133, 2009. ,
Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon ?-1?: A randomized controlled trial, J Res Med Sci Off J Isfahan Univ Med Sci, vol.16, issue.4, pp.457-62, 2011. ,
250 mg gél -Pharmacodynamie ,
,
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report, Neurol India, vol.62, issue.6, p.646, 2014. ,
, Mécanismes immunologiques des traitements de fond de la sclérose en plaques, Prat Neurol -FMC, vol.7, issue.2, pp.159-65, 2016.
The use of natalizumab for multiple sclerosis, Neuropsychiatr Dis Treat, vol.13, pp.1691-702, 2017. ,
Mécanisme d'action et applications thérapeutiques du fingolimod, MISE AU POINT, p.5 ,
Sclérose en plaques : au-delà des traitements de première ligne ,
,
,
, Sclérose en plaques : restrictions d'utilisation de LEMTRADA (alemtuzumab) face à la survenue d'effets secondaires graves
,
,
, Fiche info -MABTHERA 500 mg, solution à diluer pour perfusion -Base de données publique des médicaments
Résumé des caractéristiques du produit -MITOXANTRONE ACCORD 2 mg/mL, solution à diluer pour perfusion -Base de données publique des médicaments, Disponible sur, 2018. ,
,
Mitoxantrone et sclérose en plaques : efficacité et tolérance chez 123 patients. /data/revues/00353787/0160SUP1/34, 2008. ,
,
, Résumé des caractéristiques du produit -CYCLOPHOSPHAMIDE SANDOZ 500 mg, poudre pour solution injectable ou pour perfusion -Base de données publique des médicaments
Efficacité et tolérance du cyclophosphamide dans le traitement de fond des formes progressives de la sclérose en plaques, Rev Neurol (Paris), vol.165, issue.12, pp.1086-91, 2009. ,
, Prise en charge de la fatigue : sclérose en plaques
,
, Atelier-Troubles-vesicaux-sphincteriens-Congres
,
, La 4-aminopyridine (Fampridine) dans la SEP
, Fondation Charcot stichting, 2014.
,
Douleur et sclérose en plaques, Rev Neurol (Paris), vol.171, pp.205-211, 2015. ,
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies, Degener Neurol Neuromuscul Dis, vol.7, pp.31-45, 2017. ,
,
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, The Lancet, vol.391, pp.1263-73, 2018. ,
, Nouvelle de dernière heure : la FDA approuve le siponimod pour le traitement de la SP progressive secondaire chez l'adulte -Société canadienne de la SP
,
, Demyelinisation-remyelinisation, 2018.
,
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, doubleblind, placebo-controlled study, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.13, pp.1719-1750, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02153440
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, The Lancet, vol.383, issue.9936, pp.2213-2234, 2014. ,
Nom et Prénom de l'auteur : LEPRIEUR Alexia Adresse de l'auteur : CAEN direct research towards new therapeutics, especially for the progressive form for which the health professionals remain deprived. This thesis thus makes an inventory of knowledge of the disease : factors and mechanisms, N Engl J Med, vol.379, issue.9, pp.846-55, 2018. ,
, Sclérose en plaques, facteurs, symptômes, diagnostic, traitements, avancées thérapeutiques